Advicor

(redirected from niacin and Lovastatin)

Advicor

A once-daily proprietary combination of niacin and Lovastatin,  administered to patients with hypercholesterolaemia as an adjunct to a diet low in saturated fats and cholesterol, and other nonpharmacologic measures—e.g., exercise, omega-3 fats, soluble fibre, garlic, etc.

Adverse effects
Rash, chest pain, abdominal pain, oedema, chills, malaise, postural and orthostatic hypotension, peptic ulcers, nausea, vomiting, anorexia.
Mentioned in ?
References in periodicals archive ?
-- A single-tablet formulation of sustained-release niacin and lovastatin provides a unique and powerful array of lipid benefits.
[12.] O'Connor PJ, Rush WA, Trence DL Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
Therefore, niacin and lovastatin were found to be the most cost-effective treatments.
Patients taking niacin and lovastatin must be closely monitored by a physician because both drugs can increase liver enzymes.
We conducted an historical cohort study to evaluate the relative effectiveness of niacin and lovastatin in the treatment of dyslipidemias in patients enrolled in a health maintenance organization (HMO).
These results suggest that both niacin and lovastatin are effective in treating dyslipidemic patients in this care system, and that physicians appropriately use lovastatin more often for patients with higher baseline LDL levels and more comorbidity.
Niacin and the HMG-CoA reductase inhibitor lovastatin are both effective in lowering low-density lipoprotein (LDL) cholesterol but differ significantly in their mechanism of action, dosing, and cost.[7,8] We conducted an historical cohort study to compare the use and effectiveness of niacin and lovastatin in dyslipidemic patients enrolled in a large health maintenance organization (HMO).
Table 1 shows the demographic and clinical characteristics of the patients initially treated with niacin and lovastatin. Of patients treated with lovastatin, 57% were men, while 54% of patients treated with niacin were women.
Differences in the baseline LDL-cholesterol levels of patients treated with niacin and lovastatin are shown in Table 2.